Payment overview · 2025
General Payments
$30.27
2 reported records · 1 companies
Healthcare provider profile · identity verified
Mitchell Lee Brown, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BAYONNE, NJ · NPI 1699883306
Verified facts
What the public records show
CMS Open Payments records show Mitchell Lee Brown, M.D. received $30.27 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.27 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $30.27 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 332 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 68 |
| Alprazolam | Alprazolam | 260 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 241 | 51 |
| Losartan Potassium | Losartan Potassium | 206 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 206 | 33 |
| Meloxicam | Meloxicam | 197 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 31 |
| Gabapentin | Gabapentin | 130 | 19 |
| Metformin Hcl | Metformin Hcl | 123 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 30 |
| Furosemide | Furosemide | 111 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 96 | 34 |
| Eliquis | Apixaban | 90 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 24 |
| Celecoxib | Celecoxib | 82 | 26 |
| Azithromycin | Azithromycin | 81 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 17 |
| Potassium Chloride | Potassium Chloride | 79 | 24 |
| Tramadol Hcl | Tramadol Hcl | 77 | suppressed |
| Omeprazole | Omeprazole | 76 | 17 |
| Glimepiride | Glimepiride | 70 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 13 |
| Pregabalin | Pregabalin | 60 | 13 |
| Carvedilol | Carvedilol | 57 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 12 |
| Lisinopril | Lisinopril | 54 | 18 |
| Simvastatin | Simvastatin | 54 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 38 |
| Lactulose | Lactulose | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | 15 |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 15 |
| Meclizine Hcl | Meclizine Hcl | 45 | 15 |
| Valsartan | Valsartan | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 12 |
| Famotidine | Famotidine | 36 | 12 |
| Ketoconazole | Ketoconazole | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Linzess | Linaclotide | 34 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Rivastigmine | Rivastigmine | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Mupirocin | Mupirocin Calcium | 26 | 14 |
| Naproxen | Naproxen | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Naloxone Hcl | Naloxone Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Calcipotriene | Calcipotriene | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Prozac | Fluoxetine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30.27 · 2 records | ABBVIE INC. | CREON, LINZESS | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error